Therapeutic potential of human mesenchymal stem cells derived beta cell precursors on a nanofibrous scaffold: An approach to treat diabetes mellitus.

Abstract

Diabetes mellitus is an autoimmune and chronic disorder that is rapidly expanding worldwide due to increasing obesity. In the current study, we were able to design a reliable 3-dimensional differentiation process of human Wharton's jelly mesenchymal stem cells into pancreatic beta cell precursors (PBCPs) and detected that transplanted PBCPs could improve hyperglycemia in a diabetes-induced model in mice. Polylactic acid/chitosan nanofibrous scaffold was prepared using an electrospinning method. Quantitative real-time reverse transcription-polymerase chain reaction and immunocytochemistry analysis were carried out to assess pancreatic marker expression in the differentiated cells. PBCPs were transplanted under the kidney capsule of diabetic mice that induced streptozotocin injection 14 days before the transplantation. Moreover, an intraperitoneal glucose tolerance test (ipGTT) was carried out 2 and 4 weeks after the transplantation to measure the reaction to a sudden increase of the blood glucose level in the transplanted animals. The results indicated that the expression of SRY (sex determining region Y)-box (Sox17), forkhead box A2 (FoxA2), pancreatic and duodenal homeobox 1 (Pdx1), neurogenin 3 (Ngn3), hepatic nuclear factor 4, alpha (Hnf4α), and NK2 homeobox 2 (Nkx2.2) were increased significantly in the differentiated cells compared with that of the control group. In the current study, the diabetic disease was confirmed by measuring blood glucose and proved by conducting some other behavioral tests. After the PBCPs transplantation in a diabetic model, the ipGTT and hyperglycemia investigation during the determinant times confirmed the disease's significant improvement in the experimental models. In this study, some preclinical data suggested that the transplantation of PBCPs associated with appropriate nanofiber scaffold can be utilized for the treatment of diabetes models. In addition, studies are required to elucidate the molecular mechanism of PBCPs acting in diabetes models before being used for patients with diabetes.